J. Michael Redmond - Dec 28, 2023 Form 4 Insider Report for ORAGENICS INC (OGEN)

Role: President
Signature: /s/ Julio C. Esquivel, as Attorney-in-Fact for J Michael Redmond
Stock symbol: OGEN
Transactions as of: Dec 28, 2023
Transactions value $: $0
Form type: 4
Date filed: 1/2/2024, 05:09 PM
Previous filing: Jan 13, 2023
Next filing: Jan 2, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	OGEN	Employee Option (Right to Buy)	Award	$0	+75K		$0.00	75K	Dec 28, 2023	Common Stock	75K	$5.40	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents an award of options to purchase shares of the Company's Common Stock under the Company's 2021 Equity Incentive Plan, as amended, in connection with the Reporting Person's engagement to serve as the Company's President. 37,500 options shall vest on the December 28, 2023, the effective date of the Reporting Person's Employment Agreement with the Company (the "Effective Date"), 18,750 options shall vest on June 24, 2024, and 18,750 options shall vest on the first anniversary of the Effective Date, in each case provided the Reporting Person has remained in continuous employment with the Company through such dates. The option exercise price is the Company's closing price on the date of grant.

Content

Represents an award of options to purchase shares of the Company's Common Stock under the Company's 2021 Equity Incentive Plan, as amended, in connection with the Reporting Person's engagement to serve as the Company's President. 37,500 options shall vest on the December 28, 2023, the effective date of the Reporting Person's Employment Agreement with the Company (the "Effective Date"), 18,750 options shall vest on June 24, 2024, and 18,750 options shall vest on the first anniversary of the Effective Date, in each case provided the Reporting Person has remained in continuous employment with the Company through such dates. The option exercise price is the Company's closing price on the date of grant.